What is ClonoSIGHT?

Sequenta’s ClonoSIGHT™ test enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool, providing more accurate prognosis and monitoring for patients with lymphoid malignancies.

The test is based on the LymphoSIGHT™ technology platform, which combines proprietary multiplexed PCR assays and powerful algorithms for analysis of next-generation sequencing data.

How It Works

The ClonoSIGHT™ test uses a two-step process
that is easily integrated into patient care.

01

Identify cancer clone
in diagnostic sample

  • Identify cancer clone in diagnostic sample Identify cancer clone
    in diagnostic sample
  • Detect cancer clone in follow-up MRD samples Detect cancer clone in
    follow-up MRD samples

ClonoSIGHT Report

ClonoSIGHT test results are provided in a simple, actionable report,
which shows the MRD status and level, as well as the MRD trends over time.

Download sample report
Back to top